Yang Li

Dr. Yang Li

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
HCHuimou Chen
Huimou Chen
JHJing Hu
Jing Hu
XXXilin Xiong
Xilin Xiong
HCHongling Chen
Hongling Chen
BLBiaojun Lin
Biaojun Lin
ZLZhihua Li
Zhihua Li
Ewing’s sarcoma (ES) is a rare and highly aggressive malignant tumor arising from bone and soft tissue. Suffering from intractable or recurrent diseases, the patients’ therapy options are very limited. It is extremely urgent to identify novel potential therapeutic targets for ES and put them into use in clinical settings. In the present study, high-throughput screening of a small molecular pharmacy library was performed. The killing effect of the Aurora kinase A (AURKA) inhibitor TCS7010 in ES cells was identified, and AURKA was selected as the research object for further study. Disparate suppressants were adopted to study the cell death manner of TCS7010. TCS7010 and RNA silencing were used to evaluate the functions of AURKA in the apoptosis and ferroptosis of ES cells. Co-immunoprecipitation assay was used to investigate the correlation of AURKA and nucleophosmin1 (NPM1) in ES. Nude-mice transplanted tumor model was used for investigating the role of AURKA in ES in vivo. Investigations into the protein activities of AURKA were conducted using ES cell lines and xenograft models. AURKA was found to be prominently upregulated in ES. The AURKA expression level was remarkably connected to ES patients’ shorter overall survival (OS) and event-free survival (EFS). Furthermore, AURKA inhibition markedly induced the apoptosis and ferroptosis of ES cells and attenuated tumorigenesis in vivo. On the part of potential mechanisms, it was found that AURKA inhibition triggered the apoptosis and ferroptosis of ES cells through the NPM1/Yes1 associated transcriptional regulator (YAP1) axis, which provides new insights into the tumorigenesis of ES. AURKA may be a prospective target for clinical intervention in ES patients.

9 December 2014 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
YLYang Li
Yang Li
YQYu H. Qu
Yu H. Qu
YWYan F. Wu
Yan F. Wu
LLLing Liu
Ling Liu
XLXiang H. Lin
Xiang H. Lin
JWJing Wei
Jing Wei

22 May 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
CFChuchu Feng
Chuchu Feng
YWYu Wu
Yu Wu
YCYantao Chen
Yantao Chen
XXXilin Xiong
Xilin Xiong
PLPeng Li
Peng Li
YLYang Li
Yang Li

12 January 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
MSMingwei Su
Mingwei Su
XLXiaoshan Liu
Xiaoshan Liu
YMYuhan Ma
Yuhan Ma
XPXiaomin Peng
Xiaomin Peng
XXXilin Xiong
Xilin Xiong
YLYang Li
Yang Li
Neuroblastoma (NB), the most common extracranial solid tumor in childhood, significantly contributes to cancer‐related mortality, presenting a dearth of efficacious treatment strategies. Previously, our studies have substantiated the potent cytotoxicity of arsenic trioxide (ATO) against NB cells, however, the specific underlying mechanism remains elusive. Here, we first identified ATO as a novel GPX4 inhibitor, which could trigger the ferroptosis in NB cells. In vitro, ATO significantly inhibited the proliferation and migration ability of NB cells SK‐N‐AS and SH‐SY5Y, and induced ferroptosis. Furthermore, the iron chelator deferoxamine reversed ATO‐mediated intracellular reactive oxygen species accumulation and hindered the generation of the lipid peroxidation product malondialdehyde. Conversely, ferric ammonium citrate notably intensified its cytotoxic effects, especially on retinoic acid (RA)‐resistant SK‐N‐AS cells. Subsequently, the quantitative real‐time polymerase chain reaction results showed ATO significantly inhibited the transcription of GPX4 in NB cells. Remarkably, immunoblotting analysis revealed that MG132 exhibited a notable effect on elevating GPX4 levels in NB cells. Nevertheless, pretreatment with MG132 failed to reverse the ATO‐mediated decrease in GPX4 levels. These findings suggested that ATO reduced the GPX4 expression level in NB cells by mediating GPX4 transcriptional repression rather than facilitating ubiquitinated degradation. In conclusion, our research has successfully indicated that ATO could induce ferroptosis and initiate lipid peroxidation by regulating the transcriptional repression of GPX4, and ATO holds promise as a potential anti‐tumor agent in NB, specifically for patients with RA‐resistant HR‐NB.

1 January 2014 in Drugs of Today
Verified
Journal Article
Closed access
LLL. Liu
L. Liu
YLYang Li
Yang Li
Monoclonal antibodies (MAbs) have ushered in a new era of targeted therapy, particularly in the fields of immunotherapy and oncology. MAbs have been developed from murine antibodies to fully human antibodies, with significant improvements in immunogenicity and safety. Nevertheless, the safety of these agents is being paid close attention with relative side effects being reported. These side effects have caused many researchers' confidence in MAbs to waver. This review comprehensively summarizes the side effects of MAbs in clinical use, highlighting the prevention and management of adverse effects. Although many MAbs are well tolerated, with new MAbs continuing to be innovated, it is hard to ensure that every fresh stock of MAbs is absolutely safe. The clinical use of MAbs will face greater challenges in the future. Physicians should be on the alert for lethal side effects and treat them as soon as possible.

15 January 2011 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
YLYang Li
Yang Li
YQYu-Hua Qu
Yu-Hua Qu
YWYan-Feng Wu
Yan-Feng Wu
XWXiao-Ping Wang
Xiao-Ping Wang
JWJing Wei
Jing Wei
SHShao-Liang Huang
Shao-Liang Huang